Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04483544 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Olaparib in Cervical Cancer Patients
A Phase 2 study, sponsored by Baptist Health South Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04483544: Clinical Trial Phase 2 study, sponsored by Baptist Health South Florida.
NCT04483544 is a Phase 2 study that was terminated before completion, run by Baptist Health South Florida. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04483544, a Phase 2 study, was terminated before completion, sponsored by Baptist Health South Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The study is a non-randomized, open-label phase II clinical trial to test the investigational combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with advanced or recurrent cervical carcinoma after standard chemotherapy.
Primary Outcome
Overall objective Response Rate by Immune Response Evaluation Criteria in Solid Tumors (iRECIST) criteria (iORR)
Interventions
- DRUG pembrolizumab
- DRUG olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-12-03 |
| Est. Completion | 2024-12-12 |
| Phase | Phase 2 |
Why NCT04483544 stopped before completion
NCT04483544 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab is the first listed.
NCT04483544 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04483544 about?
NCT04483544 is a clinical study titled "Pembrolizumab and Olaparib in Cervical Cancer Patients". The study is a non-randomized, open-label phase II clinical trial to test the investigational combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with advanced or recurrent cervical carcinoma after standard chemotherapy.
What is the current status of trial NCT04483544?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-12-03. Estimated completion is 2024-12-12.
What interventions are being tested in trial NCT04483544?
The interventions under investigation include: pembrolizumab (DRUG), olaparib (DRUG).
Who is sponsoring clinical trial NCT04483544?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04483544's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI